New guidelines provide key recommendations on the management of multiple myeloma (MM), and emerging treatment recommendations are provided for both newly diagnosed myeloma patients and patients with relapsed/refractory disease, plasma cell leukemia, solitary plasmacytoma, and smoldering myeloma.